# EDGAR Filing Document

**Accession Number:** 0001401914
**File Stem:** 0001401914-26-000016
**Filing Date:** 2026-4
**Character Count:** 2610
**Document Hash:** 2aadb845fc9d60fb0fd525fb872a5f8e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001401914-26-000016.hdr.sgml**: 20260428

**ACCESSION NUMBER**: 0001401914-26-000016

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260428

**DATE AS OF CHANGE**: 20260428

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Dare Bioscience, Inc.
- **CENTRAL INDEX KEY:** 0001401914
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 204139823
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36395
- **FILM NUMBER:** 26908452

**BUSINESS ADDRESS:**
- **STREET 1:** 3655 NOBEL DRIVE
- **STREET 2:** SUITE 260
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122
- **BUSINESS PHONE:** 858-926-7655

**MAIL ADDRESS:**
- **STREET 1:** 3655 NOBEL DRIVE
- **STREET 2:** SUITE 260
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cerulean Pharma Inc.
- **DATE OF NAME CHANGE:** 20090714

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Tempo Pharmaceuticals Inc
- **DATE OF NAME CHANGE:** 20070604

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A**

PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE

SECURITIES EXCHANGE ACT OF 1934

---

| | | |
|:---|:---|:---|
| Filed by the Registrant ☒ | Filed by the Registrant ☒ | Filed by a Party other than the Registrant ☐ |
| Check the appropriate box: | Check the appropriate box: |  |
| ☐ | Preliminary Proxy Statement |  |
| ☐ | **Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2))** | **Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2))** |
| ☐ | Definitive Proxy Statement |  |
| ☒ | Definitive Additional Materials |  |
| ☐ | Soliciting Material Pursuant to § 240.14a-11(c) or § 240.14a-12 | Soliciting Material Pursuant to § 240.14a-11(c) or § 240.14a-12 |

---

**DARÉ BIOSCIENCE, INC.**

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required

☐ Fee paid previously with preliminary materials

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

------

![darebioscienceinc_vxnaxp50.jpg](darebioscienceinc_vxnaxp50.jpg)

------

![darebioscienceinc_vxnaxp50a.jpg](darebioscienceinc_vxnaxp50a.jpg)

<br>